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An unsolved challenge in the development of antigen specific immunotherapies is determining 
the optimal antigens to target. Comprehension of antigen-MHC binding is paramount towards 
achieving this goal. Here, we present CASTELO, a combined machine learning-molecular 
dynamics (ML-MD) approach to design novel antigens of increased MHC binding affinity for a 
Type 1 diabetes-implicated system. We build upon a small molecule lead optimization 
algorithm by training a convolutional variational autoencoder (CVAE) on MD trajectories of 48 
different systems across 4 antigens and 4 HLA serotypes. We develop several new machine 
learning metrics including a structure-based anchor residue classification model as well as 
cluster comparison scores. ML-MD predictions agree well with experimental binding results and 
free energy perturbation-predicted binding affinities. Moreover, ML-MD metrics are 
independent of traditional MD stability metrics such as contact area and RMSF, which do not 
reflect binding affinity data. Our work supports the role of structure-based deep learning 




Antigen specific immunotherapies for autoimmune diseases act through several mechanisms 
including inducing T-cell deletion/tolerance, eliciting anti-inflammatory T-helper 2 cells1, and 
blocking the HLA binding groove2-3, among others4. Peptide-MHC-TCR (pMHC-TCR) binding 
interactions are complex5-8, but comprehension of peptide-MHC binding is of paramount 
importance for therapeutic design. There are numerous in silico approaches to predict pMHC 
binding, with the majority combining sequence-based informatics and machine learning 
techniques to predict binding for select HLA serotypes9-12. Although the reported accuracy of 
these techniques for pMHC binding prediction is quite high13-14, confidence in MHC-II binding 
predictions remains lower, partially due to scarcity of data, ambiguity of binding registers and 
variable contributions of flanking regions9, 15-16. Structure based modeling of pMHC binding is 
able to overcome these limitations by incorporating three-dimensional atomistic 
representations rather than linear sequences17-19. Docking methods employing charge 
interactions and shape complementarity have found success in pMHC-TCR binding studies20-22, 
but are unable to account for dynamics. Molecular Dynamics (MD) simulations can explicitly 
account for important pMHC dynamic behavior such as register shifts, solvent dynamics, and 
HLA residues changing orientations within the binding cleft8, 23-25. MD simulations have been 
used previously to depict pMHC-TCR interactions26-30 and remain a rigorous standard for 
modeling pMHC binding.  
The analysis of MD simulations is often constrained to manual identification of solute 
interactions by domain experts, posing an opportunity for Machine Learning (ML) techniques to 
characterize chemical interactions in an automated and less-biased manner. Autoencoders, in 
particular, have provided advanced insights into MD trajectories31-34. Autoencoders are 
unsupervised neural networks widely used for dimensionality reduction and pattern 
recognition. Their architecture is composed of an encoder part that learns and represents an 
input into a latent space and a decoder part that reconstructs the original input using the low-
dimensional features. Variational autoencoders (VAEs) introduce the optimization constraint to 
the latent space to be normally distributed, this coerces the network to more evenly distribute 
the information into the latent space35. For MD simulation analysis, a common VAE input is a 
contact matrix from a single MD time step; hence, convolutional layers (CVAE) rather than 
regular feedforward are typically used. This leads to filter maps that can better recognize local 
patterns independently of the position.  
 In this work, we expand CASTELO34 by combining a CVAE ML pipeline with MD 
simulation to predict antigen residue binding contributions and optimize antigen-HLA binding 
for antigen specific immunotherapy design. We have previously shown using the CASTELO 
method that autoencoders trained on MD trajectories can identify unstable subdomains in 
small-molecule drug candidates for lead optimization34. In this study, we expand this 
methodology by incorporating deep learning methods to protein-protein interactions of the 
pMHC complex. We target a previously reported36 Type 1 Diabetes (T1D)-implicated cell 
population that expresses both BCR and TCR. We train our model on 48 systems consisting of 4 
HLA serotypes, 4 different antigens, and 3 binding registers per antigen. Following 500ns MD 
simulation for each system, we apply a CVAE pipeline to predict antigen residue contributions 
to binding. Based on these results, we optimize antigen residues by computing mutational 
binding affinities using Free Energy Perturbation (FEP) calculations. We report several gain-in-
affinity residue mutations for antigen specific immunotherapy design as well as novel structure-





Figure 1. HLA-antigen systems studied. (A) HLA-antigen representative structure illustrated 
using HLA-DQ8 and Insulin B9:23 peptide in register 3. The core epitope is colored cyan while 
the flanking domains are in gray. Note that only the HLA-α1 and -β1 subunits are shown for 
clarity; HLA-α2 and –β2 subunits were included in all MD simulations. (B) Studied antigen 
sequences with register 3 core epitope in bold underline. (C) Studied HLA serotypes marked 
according to their T1D disease propensity, + indicates increased risk, - indicates reduced risk37-
38. (D) HLA-antigen and register system combinations. With 4 HLA serotypes, 4 antigens and 3 
registers, a total of 48 HLA-antigen systems are included in training data.  
 
Figure 1 presents the MHC-II-antigen systems studied. Four antigens were investigated: the 
canonical insulin B:9-23 peptide, a superagonist developed by Dai and coworkers39, and two 
sequences taken from ref36: the X-idiotype and a healthy control sequence not observed in T1D 
patients. Each antigen was simulated in three registers, labeled 2-4, with register 3 
corresponding to the TCR-recognized insulin B:9-23 register40 and register 2 being one residue 
shift to the left while register 4 is one residue shift to the right. Antigen binding was 
investigated for four HLA serotypes: DQ2, DQ6, DQ7, and DQ8 with DQ2 and DQ8 holding 
enhanced risk for T1D and DQ6 and DQ7 holding reduced risk for T1D37-38. In total, 48 systems 
(4 HLAs x 4 antigens x 3 registers) were modeled using Molecular Dynamics (MD) simulations, 
each for 500ns for a total of 24μs (see Fig. S1 for representative RMSD profiles). Note that 
Figure 1 only shows the HLA-α1 and -β1 subunits, while the full HLA (α1, α2, β1, β2) molecules 
were modeled in MD simulations. Three simulation systems (X-idiotype, healthy control, and 




Figure 2. Anchor residue determination. (A) HLA-antigen cartoon illustrates anchor residues in 
orange and metric θ. θi is defined as the angle between ith residue vector and a vector from the 
antigen center to the HLA center. (B) Distribution of anchor residues and non-anchor residues 
as a function of θi and HLA-residue contact area. HLA-residue relative contact area (RCA) is 
normalized to the total surface area of residue i. (C) SVM decision boundary (solid line) and 
margins (dashed lines) to classify anchor vs. non-anchor residues. SVM mean accuracy is 
79%/95% test set/training set. (D) Plot showing linear combination of residue contact areas and 
θi which resulted in 100% accuracy of anchor residue classification for the systems studied. (E) 
Accuracy of anchor residue prediction methods. SVM classifier used both θ and RCA. LC stands 
for linear combination. Highest accuracy in both training and test sets was a linear combination 
of θ and RCA. Error bars represent 95% CI. (F) Linear combination coefficients of θ and RCA for 
100% anchor residue prediction accuracy. Error bars indicate possible range of coefficients to 
still maintain 100% prediction accuracy. Sample sizes: 48 training, 20 test.  
 
 
 Our novel method of anchor residue identification is presented in Figure 2. Anchor 
residues are antigen residues whose side chains are buried inside deep pockets in the MHC 
binding cleft. Due to their large interaction with the HLA, anchor residues make excellent 
mutation candidates for binding affinity enhancement41 or destruction42-43 and thereby 
immunotherapy optimization41-43. Anchor residues are readily identified from visual inspection 
of experimental structures using molecular visualization programs44-45. However, for large, 
structure-based pMHC binding data sets, there is a need for automated identification of anchor 
residues, which is what we address here, focusing on MHC-II binding. MHC-II antigens range in 
length from 13-25 residues46, with a 9-residue core epitope that binds inside the HLA binding 
cleft. Of this 9-residue epitope, also called a register, residues 1,4,6, and 9 are typically anchor 
residues. We sought to identify anchor residues and thus the epitope register based on 
structural metrics of the MHC-II-antigen system. 
 In order to identify anchor residues from a novel HLA-antigen structure, we combined 
antigen residue-HLA orientation, θ, with antigen residue-HLA contact area. The definition of θ is 
shown in Figure 2: for each antigen residue, a side chain vector was defined from the Cα atom 
to the terminal side chain heavy atom (Hydrogen for Glycine). Another vector is defined from 
the antigen center to the HLA center. θ is then defined as the angle between the side chain 
vector and the antigen-HLA vector. Low θ values indicate that the residue side chain is pointed 
toward the HLA like an anchor residue, while higher θ values indicate that the residue side 
chain is pointed away from the HLA. Similarly, anchor residues should have high relative contact 
area (RCA). However, as shown in Fig. 2B, anchor residues cannot be naively identified using 
these two θ and RCA metrics.  
 As a reference point to identify anchor residues vs. non-anchors, we built a Support 
Vector Machine (SVM) model, shown in Fig. 2C. This classifier identified anchor residues with 
about 95% mean accuracy for the training set. We then built a test set of 20 MHC-II-antigen 
experimental structures and compared the accuracy of the SVM to the θ and RCA metrics, as 
well as empirically-determined linear combinations of θ and RCA, Fig. 2E. The details of the test 
set are shown in Table. S1. As seen in Fig. 2E, each anchor residue identification method 
achieved high accuracy in the test set, except for the SVM. Residue orientation θ alone was 
sufficient to predict anchor residues in the test set. However, the highest accuracy in both test 
and training sets came from a linear combination of residue orientation θ and contact area RCA. 
The coefficients of the linear combination are shown in Fig. 2F. The residue orientation θ 
remains unmodified with coefficients of 1, while the first and last anchor residues have 
increased contact area RCA coefficients than the middle two anchor residues. Interestingly, the 
first anchor residue RCA coefficient can be as high as 48 (Fig. 2F, error bar) and still result in 
100% anchor residue prediction accuracy for the linear combination method. One limitation of 
our anchor residue classification methods is the small training and test set sizes (48 and 20 
respectively). This indicates that the classification methods presented here are likely overfit to 
the systems of study and should be re-evaluated with additional availability of experimental 
structures. Nevertheless, these results indicate several potential methods of naïve anchor 
residue identification for ML immunotherapy workflows.  
 
 
Figure 3. Representative CVAE analysis of epitope residue stability. (A) CVAE-ML mdV score for 
the HLA-DQ8-insulin antigen register 3 system. Red coloring reflects contribution to epitope 
binding, red: less contribution, white: more contribution. (B) CVAE-ML mdV score mapped onto 
the HLA-DQ8-insulin antigen register 3 structure, showing instability in the antigen C-terminus 
(red). Same coloring as (A). (C) CVAE-ML mdV score as a function of residue fluctuations, RMSF.  
(D) CVAE-ML mdV score as a function of residue contact area. The lack of correlation in (C-D) 
indicates the CVAE is extracting structural information distinct from residue fluctuation and 
contact area. All error bars represent 95% confidence intervals. 
 
 MD simulations typically generate extensive amounts of high-dimensional data that are 
difficult to analyze. Many ML techniques have been used to build low-dimensional 
representations of MD simulations. In our approach, we propose the use of autoencoders (AE), 
a well-known neural network architecture for dimensionality reduction tasks without the need 
of hand-crafted feature engineering. In particular, our goal is to expand the CASTELO method 
by using AEs in combination with unsupervised clustering methods to identify antigen residue 
binding contributions from a large, high-dimensional MD dataset of pMHC simulations.  
 CVAE-ML results for the insulin B:9-23 epitope binding HLA-DQ8 in register 3 
(SHLVEALYLVCGERG) are presented in Fig. 3. For simplicity, clustering results of the CVAE latent 
space were distilled into a singular residue metric, termed the dV score (detailed in the 
Methods). For simplicity, we present a modified dV score (as described in the Methods), mdV, 
to predict the residue contribution to binding proportionally from positive to negative values. A 
positive mdV score indicates the residue contributes to the binding mode, while a mdV score of 
0 indicates average contribution, and a negative mdV score indicates the residue does not 
contribute to the binding mode. The magnitude of the mdV score matters: a basic assumption 
of our work is that lower mdV scoring residues can be mutated for greater binding affinity while 
higher mdV scoring residues cannot be mutated for improvement. As shown in Fig. 3A-B, 
residue p9 Arg of the insulin epitope has a low mdV score and is hence predicted to not 
contribute to binding. This is supported by experiment which shows that a positively charged 
residue at site p9 clashes with charged HLA residues, and that mutation to a negatively charged 
residue improves binding interaction39. As seen in Fig. 3C-D, the CVAE-ML mdV score does not 
correlate to either the residue root mean square fluctuation (RMSF) or residue contact area. 
This indicates that the mdV score captures behavior independent of the RMSF and the residue 
contact area. RMSF and residue contact areas are commonly used to assess residue stability; 
however, as shown in Fig. S2, RMSF and contact area serve as poor predictors for residue 
binding contributions. The CVAE-ML mdV score predicts residue contribution to binding mode 




Figure 4. CASTELO results for novel antigen design. (A) CVAE-ML mdV score (blue) in 
comparison to mutational binding affinity changes (orange). System I is insulin p1A, II is insulin 
p9R, III is X-idiotype p6Y, IV is X-idiotype p7Y, and V is healthy control p4S, all systems are with 
HLA-DQ8 in register 3. All mutational binding affinities (orange bars) are computed from free 
energy perturbation calculations, except for system II taken from literature39-40. Labels include 
antigen identities (separated by dashed lines) and favorable mutations. Error bars represent 
95% confidence intervals. (B) Structures of optimized favorable mutants for systems II and III 
and the non-improvable system V. 
 
 Fig. 4 presents CASTELO-predicted novel antigen design results. Five residue systems 
were selected for CVAE-predicted optimization: I. p1 Ala and II. p9 Arg from HLA-DQ8 insulin 
register 3, III. p6 Tyr, and IV. p7 Tyr from HLA-DQ8 X-idiotype register 3, and a positive control 
V. p4 Ser from HLA-DQ8 healthy epitope register 3. Optimization of these residues was 
explored through mutational Free Energy Perturbation (FEP) calculations as described in the 
methods. Note that due to the expense of FEP calculations, a selected subset of residue 
mutations reflecting a range in residue hydrophobicities and sizes was initially tested and then 
expanded upon. 
 Fig. 4B illustrates selected mutations for systems II, III, and V. Mutations for system II. 
insulin p9 Arg and III. X-idiotype p6 Tyr both act to increase HLA-DQ8 binding affinity. As a 
reminder, low mdV scores indicate the residues do not contribute to binding and can be 
mutated for enhanced HLA-antigen binding affinity. Both systems are anchor residues with the 
lowest mdV score of their respective epitopes and thus made for promising mutation targets 
(see Tables S2-S4 for mdV scores of all antigen residues). The insulin R9E mutation has been 
experimentally verified to result in 100x greater binding interaction40, nicely agreeing with our 
mdV score results. Likewise, FEP calculations revealed the X-idiotype p6 Tyr residue was readily 
improved by mutation to smaller residues, with the Y6A mutation holding the largest affinity 
improvement of ∆G = -9.5 ± 1.3 kcal/mol (± 95%CI). However, mutation to a larger residue, Trp, 
resulted in worse binding affinity, ∆G = 4.5 ± 2.3 kcal/mol, shown as the positive orange bar of 
system III. in Fig. 4A. This illustrates the notion that although the CVAE-ML mdV score can 
predict a residue is not contributing to the binding mode, it does not mean that every mutation 
will be favorable. Rather, when the CASTELO CVAE-ML model predicts a residue is not 
contributing to the binding mode, that means there is a potential for binding affinity 
optimization by mutation. The CVAE-ML model, under its current form, does not predict which 
mutant residue will increase binding affinity. However, the ability to predict favorable 
mutations is greatly desired by the field and remains an active area of research. 
 Systems I and IV are predicted by CASTELO to be of roughly average contribution to the 
binding mode. Mutation free energy calculations for system IV. X-idiotype p7 Tyr do not clearly 
identify any enhanced binding affinity mutations. Most mutations for p7 remain close to zero or 
have decreased binding affinity. Free energy calculations and experimental evidence39 for 
system I. insulin p1 Ala do reveal favorable binding affinity mutations, even though the CVAE-
ML mdV score is of roughly average value. When the p1 Ala mdV score is compared across the 
epitope, it is much higher than the last 4 residues of the epitope which have low mdV scores 
(Fig. 3A, Table S3). Locally, however, the p1 Ala mdV score is the lowest within the first 5 
residues of the epitope and is the main residue to target for N-terminal epitope binding 
optimization.  
 System V. healthy control p4 Ser was selected as a positive control that could not be 
further optimized for binding affinity enhancement. This was well supported by our FEP 
calculations, which found most mutations decreased binding affinity or remained neutral. A 
cysteine mutation slightly improved binding affinity: S4C, ∆G = -1.6 ± 0.8 kcal/mol (± 95%CI). 
However, substantial binding affinity improvements were not observed, supporting the mdV 






Exploration of MHC-II-antigen binding remains an active area of research for immunology and 
immunotherapy design5. Exhaustive sampling of all possible epitopes that could bind MHC-II 
remains beyond current experimental and computational means. Therefore, directed study and 
mutation for binding affinity optimization or destruction is highly desired. Current antigen 
design methods rely on sequence-based ML models13-14 in combination with domain expertise 
of researchers39, 47. There is a need for automated, structure-based MHC-II-antigen binding 
exploration and design, which is what we have targeted here. Similarly, Ochoa et al.24 used 
structure-based approaches to predict antigen-MHC-II binding affinity by using MD simulations 
to sample conformations and docking scoring functions to rank binding affinity. This represents 
a valid approach to compare two or more antigens based on MD simulations, but lacks a 
straightforward way of identifying which residues are unstable and can be mutated for greater 
affinity. In comparison, we sought to develop a tool to help design antigen specific 
immunotherapies and optimize antigen binding by identifying per-residue binding 
contributions.    
 The existence of fixed-interval anchor residues whose side chains bury into deep HLA 
binding pockets is a unique feature of pMHC structure and is exploited by many pMHC binding 
algorithms13, 29. Anchor residues can be rapidly identified from visual inspection of pMHC 
structures. However, as more pMHC-II experimentally-resolved structures become available, 
automated determination of anchor residues will be needed for structure-based pMHC-II 
binding models. We found that a linear combination of antigen sidechain-global HLA 
orientation combined with relative contact area for each residue was sufficient to identify 100% 
of anchor residues for both the training and test sets used here. However, this model may 
suffer from overfitting and will require additional testing as more experimental structures are 
determined.  
 Our dynamics-based CVAE ML pipeline CASTELO greatly reduces the time and 
computational expense required for the design of antigen specific immunotherapies such as 
HLA-blockers or novel antigen vaccines. In our previous works of antigen mutation and binding 
affinity improvement26, 28, 48, typically only 1 in 60-100 mutations is found to improve binding 
affinity (≈-1.5kcal/mol), with a high cost of computing resources. The CVAE ML pipeline used in 
this work greatly reduces this expense by focusing our efforts on residues that have the 
potential to improve binding affinity upon mutation. In this work, for instance, our success rate 
was around 1 in 2-10 mutations found to be favorable according to FEP calculations.   
 Lastly, one limitation of this work is that although CASTELO predicts residue 
contributions to binding, it does not predict what residue mutations would be favorable 
(alanine or tryptophan, for example). Predicting which residue to mutate to de novo would 
greatly reduce computational modeling expense and remains a topic of ongoing research. 
Additionally, we compute mutational binding affinities using Free Energy Perturbation (FEP) 
calculations, which do not account for any structural changes upon mutation. Antigens are 
intrinsically disordered, capable of adopting multiple conformations even when bound to the 
MHC8, 29, 49. Ideally, we would follow-up each mutation with MD simulation50. However, given 
our experience with FEP for MHC and other systems36, 51, consistent FEP calculations of point 
mutations with only moderate error as presented here, typically do not result in drastic 





In this work, we extend the deep learning CVAE protocol CASTELO to predict per-residue 
antigen-MHC-II binding contributions and then mutate poorly binding residues to optimize 
antigen-HLA binding. We also present a structure-based anchor residue classification scheme to 
determine the binding register which is ambiguous for MHC-II antigens greater than 9 residues. 
From CVAE results, we find several residues that can be mutated for improved binding affinity 
as confirmed by experimental literature and novel Free Energy Perturbation (FEP) calculations. 
Importantly, CVAE results are found to be independent of traditional MD stability metrics such 
as RMSF and contact area, supporting its role as a novel technique for MD analysis. Our work 
presents a powerful protocol for antigen-MHC-II binding prediction and design of antigen 
specific immunotherapies.  
 
Methods  
MD Simulations. HLA-antigen systems were initially modeled using MD simulations. As 
described in our previous work36, the X-idiotype, mimotope, and healthy control systems were 
built from structure PDB ID: 5UJT, while the insulin system was taken from PDB ID: 1JK8. The X-
idiotype and healthy control antigens were mutated from the 5UJT mimotope antigen using 
VMD45. Each protein system was solvated in TIP3P water molecules with 100mM NaCl salt 
concentration. CHARMM3654 force field parameters were used for protein modeling. The 
systems were minimized for 50,000 steps with protein heavy atom constraints followed by an 
additional 50,000 steps without constraints. The systems were then equilibrated for 1ns and 
modeled for 500 ns MD simulations at 310 K with a 2 fs time step. All simulations were 
conducted using NAMD255-56 on an IBM Power8/9 cluster.  
 CASTELO Convolutional Variational Autoencoders (CVAE) were used to model each MD 
trajectory in a low-dimensional space. For the ML analysis, MD trajectories consisted of 2500 
frames saved every 200ps, for a total of 500ns simulation. Similar to previous works31-32, we 
model the input as a contact matrix/dynamism tensor between antigen and protein residues in 
each structure of the simulation. Specifically, the contact matrix has size of NxM, where N is the 
number of antigen residues and M is the number of protein residues. Considering our aim of 
finding binding patterns during the simulation, the temporal information over time is important 
to locate stable and unstable states. We enriched each time step t input using the difference of 
contacts between the current time t and a previous one t-delta. In our pipeline each time step 
of the simulation is then modeled as a tensor of 2xNxM, with the first two dimensions 
representing the contact matrix in t and the difference of the contacts in t and t-delta. We used 
CVAE to represent each contact tensor in a d-dimensional latent space, i.e. a vector of d 
elements. This intrinsically brings time steps with similar contact matrices to closer positions in 
the latent space, allowing clustering techniques to group sets of time steps with similar 
behavioral patterns. In other words, applying clustering over the latent space vectors generated 
by CVAE allows the discrimination of big clusters with several time steps of similar behavior, i.e. 
stable situation, or small clusters, i.e. unstable. We used HDBSCAN57 as our clustering 
methodology. This algorithm overcomes the limitation of knowing in advance the number of 
clusters, that is the typical drawback of partitioning techniques such as K-means, and also the 
density threshold, typically required by the standard DBSCAN. 
 Our goal is to design novel antigens by proposing favorable mutations of the antigen 
residues; for this purpose, we used a comparison between the overall antigen binding behavior 
and that of each individual residue. In our pipeline, we firstly used CVAE and HDBSCAN using 
the 2xNxM contact tensor to create a reference clustering result, i.e. an overall metric of the 
stable states during the simulation. Then, we applied the same analysis but only focusing on the 
contacts of each individual residue, i.e. using a contact matrix of size 2x1xM for each time step. 
We repeated this procedure for each residue of the antigen. With this approach we were able 
to compare the overall binding behavior with the behavior of each residue, and then propose 
antigen residues for favorable mutation. We used a modified dV metric58, mdV, in order to 
measure the disagreement between the reference clustering (with the whole contact matrix) 
and each individual residue clustering. Given two clusterings C1 and C2 of a set V with objects u 
and v in V, dV is computed as follows:  
𝑑𝑉(𝐶1, 𝐶2) = 	
∑ 𝑑!,#(𝐶1, 𝐶2)(!,#)∈'×'
|𝑉| ⋅ (|𝑉| − 1)/2  
 
Where 𝑑!,#(𝐶1, 𝐶2) is 1 if clusterings C1 and C2 disagree: 𝐶1(𝑢) = 𝐶1(𝑣)	𝑎𝑛𝑑	𝐶2(𝑢) ≠
𝐶2(𝑣), or 𝐶1(𝑢) ≠ 𝐶1(𝑣)	𝑎𝑛𝑑	𝐶2(𝑢) = 𝐶2(𝑣), and 0 otherwise. The modified dV metric, mdV, 
is found by subtracting dV by 1: 1-dV and then normalizing the mean to 0. This results in the 
mdV indicating less binding contribution if negative and more stable binding contribution if 
positive, making it more intuitive to visually compare in plots. 
 In order to have reliable results, we repeated the whole pipeline with different CVAE 
hyper-parameters. Specifically we used a grid-parameterization varying the number of latent 
dimensions: dϵ(3, 5, 10) and the time delta for the contact tensor definition: deltaϵ(10, 25, 50) 
time steps. The CVAE structures we used were fixed, having specular encoder and decoder 
networks, with 4 layers each with 32 convolutional filters of size 1x7. We trained a total of 9 
different CVAE architectures and averaged the clustering results given by each one. We 
parameterized HDBSCAN clustering algorithm with a minimum cluster size of 50 and both leaf 
size and minimum samples of 3. 
 Free Energy Perturbation. Based on CVAE results, several systems were selected for 
mutational binding affinity calculations: insulin DQ8 register3, x-idiotype DQ8 register3, and 
healthy control DQ8 register 3. Binding affinity changes were computed using Free Energy 
Perturbation calculations based on previous work51, 59-62 employing a custom short-range 
potential on NAMD2. Initial structures for FEP calculations were taken from the last frame of 
MD simulations based on RMSD analysis showing structural stability (<0.35 Å) for 300+ ns. All 
FEP calculations were conducted over a course of 34 𝜆 windows with at least 200 ps per 
window for a total of 6.8+ ns per calculation. All FEP calculations were computed with 5 replicas 
and averaged for the final ∆∆G value. All error bars in this work are 95% CI unless otherwise 
noted.   
 All structures are visualized with VMD while all plots are constructed with matplotlib. 
The SVM used to classify anchor residues was built using the scikit-learn library with a radial 
basis function kernel, regularization parameter C=30, and kernel coefficient gamma=0.03. 
Optimal parameters were determined using a grid search. 
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Figure S1. Representative RMSD profiles of HLA-antigen systems studied via Free Energy 
Perturbation. Note: only the HLA-α1 and HLA-β1 subunits are included in the RMSD calculation. 
The final structure from each trajectory was extracted for FEP calculation. 
 
 
Fig. S2. RMSF and relative contact area as predictors of residue binding contributions. As seen 
in the bar plot, RMSF and contact area values show greater stability for all 5 selected residue 
systems. However, the systems II and III are predicted not contributing to binding stability and 
can thus be optimized for more favorable binding affinity. This illustrates that RMSF and 
relative contact areas do not capture residue contributions to binding stability, while the mdV 
metric used in this work is able to capture contributions to binding stability. All error bars are 
95% CI. Residue mdV, RMSF, and contact area values are all relative to the 0-mean residue 
value for the antigen. 
  




Serotype Antigen Sequence 
Expt. Accuracy 
(Å) 
1fv1 HLA-DR2a NPVVHFFKNIVTPRTPPPSQ 1.9 
1j8h HLA-DR4 PKYVKQNTLKLAT 2.4 
1sjh HLA-DR1 PEVIPMFSALSEG 2.25 
1uvq HLA-DQ6 MNLPSTKVSWAAVGGGGSLV 1.8 
2fse HLA-DR1 AGFKGEQGPKGEPG 3.1 
2nna HLA-DQ8 SGEGSFQPSQENP 2.1 
2q6w HLA-DR52a AWRSDEALPLG 2.25 
4i5b HLA-DR1 VVKQNCLKLATK 2.12 
4is6 HLA-DR4 RQLYPEWTEAQRL 2.5 
4ozh HLA-DQ2 APQPELPYPQPGS 2.8 
4ozi HLA-DQ2 QPFPQPELPYP 3.2 
5ksa HLA-DQ8 QPQQSFPEQEA 2 
5ksu HLA-DQ2.5 PVSKMRMATPLLMQ 2.73 
5ksv HLA-DQ2.5 MATPLLMQALPM 2.19 
5lax HLA-DRB4 SKGLFRAAVPSGAS 2.6 
6biy HLA-DRB1 DIFERIASEASRL 2.05 
6cpl HLA-DR11 VDRFYKTLRAEQASQE 2.45 
6dig HLA-DQ6 AGNHAAGILTLGK 2 
6hby HLA-DR1 ARRPPLAELAALNLSGSRL 1.95 
6u3m HLA-DQ2.5 QPMPMPELPYP 1.9 
 








mean-1 95% CI 
1_CYS 18 0.409 0.131 0.591 1.147 0.147 0.117 
2_ALA 18 0.371 0.078 0.629 1.221 0.221 0.070 
3_ARG 18 0.483 0.049 0.517 1.004 0.004 0.044 
4_GLN 18 0.437 0.107 0.563 1.093 0.093 0.096 
5_GLU 18 0.493 0.08 0.507 0.984 -0.016 0.072 
6_ASP 18 0.519 0.066 0.481 0.934 -0.066 0.059 
7_THR 18 0.534 0.069 0.466 0.905 -0.095 0.062 
8_ALA 18 0.517 0.062 0.483 0.938 -0.062 0.056 
9_MET 18 0.53 0.055 0.47 0.912 -0.088 0.049 
10_VAL 18 0.509 0.066 0.491 0.953 -0.047 0.059 
11_TYR 18 0.562 0.074 0.438 0.850 -0.150 0.066 
12_TYR 18 0.485 0.076 0.515 1.000 0.000 0.068 
13_PHE 18 0.505 0.068 0.495 0.961 -0.039 0.061 
14_ASP 18 0.496 0.113 0.504 0.978 -0.022 0.101 
15_TYR 18 0.421 0.16 0.579 1.124 0.124 0.143 
16_TRP 18 0.487 0.128 0.513 0.996 -0.004 0.115 
 
 








mean-1 95% CI 
1_SER 18 0.515 0.06 0.485 0.839 -0.161 0.048 
2_HSE 18 0.483 0.069 0.517 0.894 -0.106 0.055 
3_LEU 18 0.5 0.095 0.5 0.865 -0.135 0.076 
4_VAL 18 0.266 0.131 0.734 1.270 0.270 0.105 
5_GLU 18 0.357 0.108 0.643 1.112 0.112 0.086 
6_ALA 18 0.436 0.146 0.564 0.976 -0.024 0.117 
7_LEU 18 0.336 0.135 0.664 1.149 0.149 0.108 
8_TYR 18 0.305 0.141 0.695 1.202 0.202 0.113 
9_LEU 18 0.324 0.125 0.676 1.170 0.170 0.100 
10_VAL 18 0.41 0.084 0.59 1.021 0.021 0.067 
11_CYS 18 0.484 0.074 0.516 0.893 -0.107 0.059 
12_GLY 18 0.478 0.118 0.522 0.903 -0.097 0.094 
13_GLU 18 0.482 0.1 0.518 0.896 -0.104 0.080 
14_ARG 18 0.509 0.123 0.491 0.849 -0.151 0.098 
15_GLY 18 0.445 0.084 0.555 0.960 -0.040 0.067 
 
 










1 95% CI 
1_CYS 18 0.458 0.153 0.542 0.917 -0.083 0.120 
2_ALA 18 0.368 0.172 0.632 1.069 0.069 0.134 
3_ARG 18 0.427 0.172 0.573 0.970 -0.030 0.134 
4_GLN 18 0.417 0.187 0.583 0.987 -0.013 0.146 
5_ARG 18 0.453 0.217 0.547 0.926 -0.074 0.170 
6_PHE 18 0.348 0.197 0.652 1.103 0.103 0.154 
7_TRP 18 0.401 0.21 0.599 1.014 0.014 0.164 
8_SER 18 0.36 0.212 0.64 1.083 0.083 0.166 
9_GLY 18 0.429 0.18 0.571 0.966 -0.034 0.141 
10_PRO 18 0.403 0.218 0.597 1.010 0.010 0.170 
11_LEU 18 0.422 0.194 0.578 0.978 -0.022 0.152 
12_PHE 18 0.384 0.183 0.616 1.042 0.042 0.143 
13_ASP 18 0.416 0.2 0.584 0.988 -0.012 0.156 
14_TYR 18 0.429 0.196 0.571 0.966 -0.034 0.153 
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